

Supplementary table 1: Characteristics of included versus excluded participants

Characteristics	Excluded participants	Included participants
N	1753	946
Age, mean [SD]	38.9 (12.0)	36.7 (12.3)
Sex (men)	484 (27.6)	298 (31.5)
Smoking		
Non-smoker	1482 (84.5)	855 (90.4)
Smoker	271 (15.5)	91 (9.6)
Alcohol consumption		
Non-drinker	713 (40.7)	355 (37.5)
Drinker consuming		
< 1 go/day	757 (43.3)	442 (46.7)
≥ 1 go/day	280 (16.0)	149 (15.8)
Missing	3	
Leisure time physical activity		
Non-engagement	375 (21.4)	197 (20.8)
< 150 min/week	1220 (69.7)	657 (69.5)
≥ 150 min/week	156 (8.9)	92 (9.7)
Missing	2	
Comorbidity	91 (5.2)	29 (3.1)
Lung disease	62 (3.5)	18 (1.9)
Heart disease	22 (1.3)	5 (0.5)
Cancer	17 (1.0)	6 (0.6)
History of SARS-Cov-2 infection ^a	27 (1.5)	5 (0.5)
Vaccine-to-IgG test days, median [range] ^b	62 [5-103]	67 [15-103]
Missing	220	0
SARS-Cov-2 spike IgG (AU/mL), median [range]	5708 [0-61922]	5588 [135-36962]
Missing	16	0
Central obesity ^c	203 (21.9)	187 (19.8)
Missing	826	
High BP ^d	256 (25.1)	213 (22.5)
Missing	732	
High FPG ^e	17 (18.3)	65 (6.9)
Missing	1660	
High TG ^f	159 (16.0)	93 (9.8)
Missing	761	
Reduced HDL-C ^g	45 (3.7)	30 (3.2)
Missing	535	

Values are n (%), unless otherwise stated; SD: standard deviation; IgG: immunoglobulin G;

^a positive result of either polymerase chain reaction test or the measurement of antibodies against SARS-CoV-2 nucleocapsid protein; ^b time interval between the second dose of vaccine and the day of blood draw;

^c waist circumference ≥ 90 cm for men, or ≥ 80 cm for women; ^d systolic blood pressure [BP] ≥ 130 mmHg, diastolic BP ≥ 85 mmHg or using antihypertensive medication; ^e fasting plasma glucose ≥ 100 mg/dL or using antidiabetic medication; ^f triglycerides ≥ 150 mg/dL or using lipid-lowering medication; ^g high-density lipoprotein cholesterol < 40 mg/dL for men, or < 50 mg/dL for women.

Supplementary table 2: Association between MetS and SARS-Cov-2 spike IgG titers, excluding those with history of SARS-Cov-2 infection and those with comorbid cancer, heart or lung diseases

MetS/ number of MetS components	N	SARS-Cov-2 spike IgG			
		Model 1		Model 2	
		GMT (95% CI)	GMR (95% CI)	GMT (95% CI)	GMR (95% CI)
Metabolic syndrome					
MetS (-)	865 5309 (5049, 5582)	1.00 (ref)	5051 (4636, 5503)	1.00 (ref)	
MetS (+)	47 4020 (3278, 4929)	0.76 (0.61, 0.93)	3816 (3136, 4644)	0.76 (0.62, 0.92)	
Number of metabolic syndrome components					
0	552 5387 (5046, 5750)	1.00 (ref)	5057 (4593, 5568)	1.00 (ref)	
1	225 5425 (4944, 5952)	1.01 (0.90, 1.13)	5217 (4686, 5807)	1.03 (0.93, 1.15)	
2	88 4678 (4022, 5440)	0.87 (0.73, 1.03)	4550 (3882, 5331)	0.90 (0.77, 1.05)	
3	30 4233 (3282, 5459)	0.79 (0.60, 1.03)	4245 (3335, 5404)	0.84 (0.66, 1.07)	
≥ 4	17 3554 (2548, 4957)	0.66 (0.47, 0.93)	3094 (2270, 4218)	0.61 (0.45, 0.84)	
P for trend		0.006		0.006	

MetS: Metabolic syndrome; GMT: geometric mean titers; GMR: geometric mean ratio; ref: reference; Model 1: adjusted for age and sex; Model 2: adjusted for age, sex, smoking, alcohol consumption, leisure time physical activity, and time interval (in day) between the second vaccination and the day of blood draw